1.57
+0.07(+4.67%)
Currency In USD
| Previous Close | 1.5 |
| Open | 1.52 |
| Day High | 1.6 |
| Day Low | 1.49 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.87 |
| Volume | 1.13M |
| Average Volume | 1.07M |
| Market Cap | 58.16M |
| PE | -2.12 |
| EPS | -0.74 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 1.62 |
| Change | 0.07 |
If you invested $1000 in MAIA Biotechnology, Inc. (MAIA) since IPO date, it would be worth $352.02 as of March 12, 2026 at a share price of $1.57. Whereas If you bought $1000 worth of MAIA Biotechnology, Inc. (MAIA) shares 3 years ago, it would be worth $414.25 as of March 12, 2026 at a share price of $1.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Mar 04, 2026 9:00 PM GMT
Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceu
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Mar 03, 2026 3:45 AM GMT
Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceu
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Mar 02, 2026 10:00 PM GMT
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commence